Global Epigenetics Market 2014-2018 - Product Image

Global Epigenetics Market 2014-2018

  • ID: 2716874
  • November 2013
  • Region: Global
  • 43 Pages
  • TechNavio
1 of 5


  • Celgene Corp.
  • Eisai Inc.
  • Merck & Co.
  • MORE

The analysts forecast the Global Epigenetics Market to grow at a CAGR of 28.79 percent for the period 2013–2018. Several driving factors and trends will contribute to this growth—all of which will be outlined with detail in this report.

The analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers and challenges, and a number of other factors to provide the most accurate and detailed market research reports possible.

A more specific breakdown of this report's contents is below.

Overview of market share and landscape for the following key geographies:

- Americas

Overview and impact analysis of:

- 3 Market Drivers
- 3 Market Challenges
- 3 Market Trends

Market Shares and SWOT Analysis for these vendors:
- Celgene Corp.
- Eisai Inc.
- Merck & Co.

Five Force Model Impact Analysis of:

- Suppliers
- Buyers
- Substitutes
- New entrants
- Market competition

Note: All of the segments above are supplemented with a combination of statistical data, graphical analysis, and verbal explanation.

After purchasing any of our reports, you can request a one hour meeting to discuss any questions you may have with our team of analysts.

Note: Product cover images may vary from those shown
2 of 5


  • Celgene Corp.
  • Eisai Inc.
  • Merck & Co.
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.3 Product Profile
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Mechanism of Action
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
17. Key Vendor Analysis
17.1 Celgene Corp.
17.1.1 Business Overview
17.1.2 Key Information
17.1.3 SWOT Analysis
17.2 Eisai Inc.
17.2.1 Business Overview
17.2.2 Key Information
17.2.3 SWOT Analysis
17.3 Merck & Co. Inc.
17.3.1 Business Overview
17.3.2 Business Segmentation
17.3.3 Key Information
17.3.4 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Epigenetics Market 2013-2018 (US$ million)
Exhibit 3: Global Epigenetics Market Segmentation by Mechanism of Action
Exhibit 4: Business Segmentation of Merck & Co., Inc.

Note: Product cover images may vary from those shown
3 of 5


  • Celgene Corp.
  • Eisai Inc.
  • Merck & Co.
  • MORE

Commenting on the report, an analyst from the team said: “Along with oncology indications, epigenetic drugs also find application in non-oncology indications such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders, and personalized medicine. These are some of the high growth and emerging areas that are expected to drive the Global Epigenetics market in the future. Current treatments for chronic and degenerative disorders are in many cases inadequate or very expensive. Epigenetic drugs are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal transcriptional state.”

According to the report, one of the main drivers propelling the growth of the market is the steadily growing aging population worldwide. There is a strong correlation between cancer and aging. The number of patients suffering from cancer is increasing owing to the increasing aging population, both in developing and developed nations.

Further, the report states that one of the major challenges faced by the market is the patent expiries of major drugs. Patent expiries erode the revenue potential of the market and affect the market negatively.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown
4 of 5

- Celgene Corp.
- Eisai Inc.
- Merck & Co.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown




Our Clients

  • Promega Corporation
  • Roche Diagnostics Ltd.
  • KeyGene N.V.
  • Celera Corporation
  • Qiagen N.V.
  • University of California at Santa Barbara